8-K: Oncotelic Secures $560K Note, Up to $25M Equity Line

Oncotelic Therapeutics, Inc. has entered into a convertible promissory note agreement for $560,000 and an equity purchase agreement for up to $25 million with Mast Hill Fund, LP.

Summary

• On July 31, 2025, Oncotelic Therapeutics, Inc. entered into a Securities Purchase Agreement with Mast Hill Fund, LP, issuing a convertible promissory note for a gross principal amount of $560,000.
• The $560,000 note has a 10% original issue discount, carries a 10% annual interest rate, and matures on the earlier of one year, acceleration upon default, or full prepayment.
• The note is convertible into common stock at a fixed price of $0.07 per share, subject to adjustments.
• The company also issued 2,000,000 warrants to Mast Hill with an exercise price of $0.15 per share.
• Both the new $560,000 note and a prior $605,000 note from May 2022 are secured against the company's assets, excluding equity interests and assets within the joint venture with Dragon Overseas Capital Limited (GMP Biotechnology and its subsidiaries).
• Secured assets include OT-101, CA4P, Oxi4503, AI and AI CDMO technologies, and the nanoparticle platform.
• Proceeds from the $560,000 note are designated for general working capital, with specific restrictions on use (e.g., no repayment to officers/directors, no loans/investments outside existing operations).
• On August 1, 2025, the company entered into an Equity Purchase Agreement with Mast Hill, granting Oncotelic the right, but not the obligation, to sell up to $25 million in common stock to Mast Hill in multiple tranches.
• Under the equity agreement, the company can submit 'Put Notices' for amounts between $5,000 and the lesser of $500,000 or 20% of the Average Daily Trading Value.
• In exchange for the equity agreement, Oncotelic issued 3,350,000 warrants to Mast Hill and committed to filing a registration statement for the resale of shares issued under the equity agreement within 60 calendar days.
• The purchase price for shares under the equity agreement will be 97% of the Market Price or 102% of the Market Alternative Price.

Sentiment

Score: 4

Explanation: While securing capital is positive for a development-stage biotech, the terms of the financing (high interest, significant dilution potential from convertible note, warrants, and discounted equity sales, and secured debt) are quite unfavorable for existing shareholders. It provides necessary liquidity but at a high cost and significant future dilution.

Positives

• Secured immediate funding of $560,000 for general working capital, which is crucial for ongoing operations.
• Established a flexible equity line of credit for up to $25 million, providing a potential source of significant future capital.
• The equity purchase agreement allows the company to control the timing and amount of capital raises, providing flexibility.

Negatives

• The $560,000 convertible note carries a high interest rate of 10% per annum and a 10% original issue discount, increasing the cost of capital.
• The note and a prior $605,000 note are secured against substantially all of the company's core assets, which could limit future financing options or impact creditors in case of default.
• Significant potential for shareholder dilution from the conversion of the $560,000 note at $0.07 per share, the issuance of 2,000,000 warrants at $0.15, and the 3,350,000 warrants issued for the equity agreement.
• Further dilution is expected from future sales of common stock under the $25 million equity purchase agreement, especially at a discount (97% of Market Price).

Risks

• Significant shareholder dilution due to the convertible note, warrants, and potential future equity sales at a discount.
• The company's assets are secured by the convertible notes, which could impact its ability to secure additional debt financing.
• Reliance on Mast Hill Fund, LP for future capital raises under the equity purchase agreement, which is at the company's discretion but subject to Mast Hill's obligations.
• Potential for acceleration of the convertible note's maturity upon an Event of Default, leading to immediate cash repayment obligations.
• Market price volatility could impact the effectiveness and dilutive effect of the equity purchase agreement, as shares are purchased at a discount to market price.

Future Outlook

The company has secured a potential future funding source of up to $25 million through the equity purchase agreement, which it can utilize at its discretion over a 24-month period or until the maximum commitment is reached. This provides a flexible mechanism for future capital raises to support general working capital needs.

Industry Context

For a biotechnology company like Oncotelic Therapeutics, securing capital is paramount for funding research, clinical trials, and general operations. This financing arrangement, while providing necessary liquidity, reflects a common challenge for early to mid-stage biotech firms in accessing capital, often leading to dilutive and high-cost financing structures. The use of convertible notes and equity lines with discounts is a typical strategy for companies that may have limited access to traditional debt or equity markets due to their developmental stage and lack of consistent revenue.

Comparison to Industry Standards

• The 10% interest rate and 10% original issue discount on the convertible note are relatively high, indicating a higher cost of capital compared to more established companies or those with stronger balance sheets. This is common for smaller, development-stage biotech firms.
• The secured nature of the convertible notes against core assets (OT-101, CA4P, Oxi4503, AI, nanoparticle platform) is a significant concession, often seen when a company's financial position necessitates stronger collateral for lenders.
• The equity purchase agreement, allowing sales at 97% of market price, is a standard 'at-the-market' or 'equity line' facility, but the discount implies immediate dilution for existing shareholders on each 'put' exercised. This is a common financing tool for micro-cap and small-cap companies, but the terms can be more favorable for companies with stronger market capitalization and trading liquidity.
• The issuance of substantial warrants (2 million for the note, 3.35 million for the EPA) is a typical sweetener for investors providing high-risk capital to biotech companies, further contributing to potential dilution.

Stakeholder Impact

• Shareholders: Face significant potential dilution from the conversion of the note, the exercise of warrants, and future equity sales under the $25 million agreement, especially given the discounted purchase price.
• Creditors: The existing and new convertible notes are secured against the company's core assets, which could impact the recovery prospects of unsecured creditors in a liquidation scenario.
• Employees: The secured funding provides working capital, which helps ensure continued operations and employment.

Next Steps

• The company is required to file a registration statement with the SEC within 60 calendar days of August 1, 2025, to register the shares issuable under the Equity Purchase Agreement for resale.

Key Dates

Recommendation

The company has secured critical funding, which is essential for its continued operations as a development-stage biotech. However, the terms of the financing are highly dilutive and expensive, including a high-interest secured convertible note and an equity line that allows for sales at a discount to market. While the capital infusion provides a lifeline and operational runway, the significant potential for future dilution and the high cost of capital weigh heavily on shareholder value. Investors should 'hold' to monitor the company's progress in utilizing this capital for its pipeline development and to assess the actual dilutive impact as the equity line is drawn upon, rather than 'buy' given the unfavorable financing terms or 'sell' given the immediate liquidity provided.

Keywords

Oncotelic Therapeutics, OTLC, Mast Hill Fund, Convertible Note, Equity Purchase Agreement, SEC Filing, 8-K, Biotechnology, Capital Raise, Dilution, Warrants, Secured Debt, Working Capital